Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-Comb is a polymeric nanoparticle radiolabeled with the positron-emitting isotope Copper-64 (64Cu). It is designed for use in Positron Emission Tomography (PET) imaging. In the provided context, it primarily serves as a non-targeted control or as a foundational component for the development of targeted imaging agents, such as 64Cu-CANF-Comb, which is conjugated with C-type atrial natriuretic factor (CANF) to specifically target natriuretic peptide clearance receptors (NPRC) in atherosclerotic plaque.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 64Cu-Comb.